Get the Stockscreener App
9.22
0.44%
0.04
Indivior Plc stock is traded at $9.22, with a volume of 311.22K.
It is up +0.44% in the last 24 hours and down -11.52% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$9.18
Open:
$9.18
24h Volume:
311.22K
Relative Volume:
0.44
Market Cap:
$1.19B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-383.00M
1W Performance:
+0.66%
1M Performance:
-11.52%
6M Performance:
-48.64%
1Y Performance:
-54.11%
1-Day Range:
$9.15
$9.24
1-Week Range:
$8.83
$9.395
52-Week Range:
$7.33
$23.22
Indivior Plc Stock (INDV) Company Profile
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-13-23 | Initiated | Northland Capital | Outperform |
Indivior Plc Stock (INDV) Latest News
242,500 Shares in Indivior PLC (NASDAQ:INDV) Bought by AlphaCentric Advisors LLC - MarketBeat
Indivior completes refinancing of secured term loan - Marketscreener.com
Indivior Extends Its Debt Maturity With Refinancing of Term Loan - BNN Bloomberg
Indivior Boosts Shareholder Value with Repurchase Program - TipRanks
Indivior Boosts Liquidity with $400 Million Refinancing - TipRanks
Indivior PLC Completes Refinance of Secured Term Loan - Marketscreener.com
VELA Investment Management LLC Acquires 108,435 Shares of Indivior PLC (NASDAQ:INDV) - MarketBeat
When the Price of (INDV) Talks, People Listen - Stock Traders Daily
Indivior Announces Total Voting Rights Update - TipRanks
Indivior (LON:INDV) Stock Price Crosses Below 200 Day Moving AverageWhat's Next? - MarketBeat
Suboxone Tooth Decay Lawsuit - Lawsuit Information Center Blog
Sublocade shows promise in opioid disorder recovery By Investing.com - Investing.com Australia
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month - The Malaysian Reserve
Sublocade shows promise in opioid disorder recovery - Investing.com India
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Ab - StreetInsider.com
Indivior PLC Strengthens Position with Share Buyback - TipRanks
Mediolanum International Funds Ltd Purchases Shares of 124,624 Indivior PLC (NASDAQ:INDV) - MarketBeat
Indivior's (INDV) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Indivior price target raised to $16 from $15 at Piper Sandler - TipRanks
Indivior stock target increased, overweight on strong earnings By Investing.com - Investing.com UK
Indivior PLC (INDV) Surpasses Q3 Earnings and Revenue Estimates - MSN
Earnings call: Indivior PLC reports strong Q3 revenue growth, eyes expansion - Investing.com Nigeria
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ... - Yahoo Finance
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Competitive ... By GuruFocus - Investing.com Canada
Indivior Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
Indivior (NASDAQ:INDV) Shares Gap UpWhat's Next? - MarketBeat
Severn Trent, Bloomsbury, Indivior: What brokers said today - Proactive financial news
FTSE 250 movers: Softcat, Indivior and Bloomsbury Publishing surge after results - ShareCast
Indivior (LON:INDV) Trading 11.9% HigherWhat's Next? - MarketBeat
Indivior shares motor 11% after reassuring update; brokers positive - Proactive Investors USA
Indivior shares soar 10% after Q3 results beat estimates and guidance update - Investing.com India
Indivior, Humana and Centene report expected settlement of antitrust litigation - TipRanks
Demand for opioid treatment drug drives growth at Indivior - Yahoo Finance UK
Indivior reports Q3 adjusted EPS 54c, consensus 31c - TipRanks
Indivior confident after strong third quarter - ShareCast
Indivior Announces Q3 2024 Financial Results - The Malaysian Reserve
Indivior moves to shore up confidence in Sublocade - Proactive Investors Australia
Indivior PLC Reports Strong Q3 2024 Performance - TipRanks
Indivior PLC (INDV) Q3 2024 Earnings Report Preview: What to Exp - GuruFocus.com
Indivior PLC Continues Aggressive Share Buyback - TipRanks
Two Seas Capital LP Increases Stake in Indivior PLC - Yahoo Finance
Indivior (NASDAQ:INDV) Stock Price Up 3.9%Time to Buy? - MarketBeat
Indivior falls as headwinds to Sublocade prompt another guidance cut - MSN
Indivior PLC Completes Share Buyback Milestone - TipRanks
Indivior to Release Key 2024 Financial Results - TipRanks
Indivior PLC (NASDAQ:INDV) Sees Large Decrease in Short Interest - MarketBeat
Indivior price target lowered to 1,400 GBp from 2,100 GBp at Stifel - TipRanks
Barclays, Bunzl, Indivior: What brokers said today - Proactive financial news
Indivior price target slashed after second profit warning of the year - Proactive Investors USA
Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025 - Seeking Alpha
Indivior price target lowered to $16 from $20 at Craig-Hallum - Yahoo Finance
Indivior Plc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):